N-Oct 5 is generated by in vitro proteolysis of the neural POU-domain protein N-Oct 3

被引:8
作者
Atanasoski, S
Schreiber, E
Fontana, A
Herr, W
机构
[1] COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA
[2] UNIV ZURICH HOSP, DEPT INTERNAL MED, DIV CLIN IMMUNOL, CH-8044 ZURICH, SWITZERLAND
[3] CALYDON INC, MENLO PK, CA 94025 USA
关键词
EMSA; transcription; DNA-binding; protease inhibitors;
D O I
10.1038/sj.onc.1200953
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The neural POU-domain proteins N-Oct 3 and N-Oct 5 were first identified in electrophoretic mobility retardation assays through their ability to bind to the octamer sequence ATGCAAAT. These two N-Oct factors are detected in extracts from tumor-derived and normal neural cells. They are present differentially, however, in extracts from melanocytes and melanoma cells: N-Oct 3 is present in extracts from both melanocytes and melanoma cells, whereas N-Oct 5 is more evident in extracts from metastatic melanoma cells. We show here that a cDNA encoding N-Oct 3 directs synthesis of both the N-Oct 3 and N-Oct 5 proteins and that the N-Oct 5 protein in neural and melanoma-cell extracts is also related to N-Oct 3. N-Oct 5, however, is apparently not expressed in vivo: It is not detected if cells are rapidly lysed in SDS or if extracts are prepared with a cocktail of protease inhibitors that includes the serine-protease inhibitor 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF). These data suggest that N-Oct 5 is a specific in vitro proteolytic cleavage product of N-Oct 3 and is not directly related to melanocyte malignancy.
引用
收藏
页码:1287 / 1294
页数:8
相关论文
共 31 条
[1]  
ANGUS J, 1995, ONCOGENE, V11, P691
[2]  
[Anonymous], 1988, Antibodies: A Laboratory Manual
[3]   AN AMINO-TERMINAL FRAGMENT OF GAL4 BINDS DNA AS A DIMER [J].
CAREY, M ;
KAKIDANI, H ;
LEATHERWOOD, J ;
MOSTASHARI, F ;
PTASHNE, M .
JOURNAL OF MOLECULAR BIOLOGY, 1989, 209 (03) :423-432
[4]   DIFFERENTIAL POSITIVE CONTROL BY OCT-1 AND OCT-2 - ACTIVATION OF A TRANSCRIPTIONALLY SILENT MOTIF THROUGH OCT-1 AND VP16 CORECRUITMENT [J].
CLEARY, MA ;
STERN, S ;
TANAKA, M ;
HERR, W .
GENES & DEVELOPMENT, 1993, 7 (01) :72-83
[5]  
DAS G, 1993, J BIOL CHEM, V268, P25026
[6]   A LIVER-ENRICHED TRANSCRIPTIONAL ACTIVATOR PROTEIN, LAP, AND A TRANSCRIPTIONAL INHIBITORY PROTEIN, LIP, ARE TRANSLATED FROM THE SAME MESSENGER-RNA [J].
DESCOMBES, P ;
SCHIBLER, U .
CELL, 1991, 67 (03) :569-579
[7]   PURIFICATION OF A RAS-RESPONSIVE ADENYLYL CYCLASE COMPLEX FROM SACCHAROMYCES-CEREVISIAE BY USE OF AN EPITOPE ADDITION METHOD [J].
FIELD, J ;
NIKAWA, J ;
BROEK, D ;
MACDONALD, B ;
RODGERS, L ;
WILSON, IA ;
LERNER, RA ;
WIGLER, M .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (05) :2159-2165
[8]   A CNS-SPECIFIC POU TRANSCRIPTION FACTOR, BRN-2, IS REQUIRED FOR ESTABLISHING MAMMALIAN NEURAL CELL LINEAGES [J].
FUJII, H ;
HAMADA, H .
NEURON, 1993, 11 (06) :1197-1206
[9]   STRUCTURE AND EVOLUTION OF 4 POU DOMAIN GENES EXPRESSED IN MOUSE-BRAIN [J].
HARA, Y ;
ROVESCALLI, AC ;
KIM, Y ;
NIRENBERG, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (08) :3280-3284
[10]   THE POU DOMAIN - VERSATILITY IN TRANSCRIPTIONAL REGULATION BY A FLEXIBLE 2-IN-ONE DNA-BINDING DOMAIN [J].
HERR, W ;
CLEARY, MA .
GENES & DEVELOPMENT, 1995, 9 (14) :1679-1693